= SPIRIT 2025 Checklist
<spirit-2025-checklist>
#quote(block: true)[
Scope: Standard Protocol Items: Recommendations for Interventional
Trials.

Reference: See `source/archetypes/spirit-2025.yml` for canonical link
and provenance.
]

== Instructions
<instructions>
- Use the boxes to confirm each reporting item.
- Add reviewer notes under each section as needed.

== Administrative information
<administrative-information>
- ☐ #strong[\1. Title:] Descriptive title that identifies the study as a
  randomised trial, the interventions, the trial acronym, and the SPIRIT
  item this protocol is based on.
- ☐ #strong[\2. Trial registration:] Trial identifier and registry name.
  If not yet registered, name of intended registry.
- ☐ #strong[\3. Protocol version:] Date and version identifier.
- ☐ #strong[\4. Funding:] Sources and types of financial, material, and
  other support.
- ☐ #strong[\5. Roles and responsibilities:] Names, affiliations, and
  roles of protocol contributors.

== Introduction
<introduction>
- ☐ #strong[\6. Background and rationale:] Description of research
  question and justification for undertaking the trial, including
  summary of relevant studies.
- ☐ #strong[\7. Objectives:] Specific objectives or hypotheses.

== Methods: Participants, interventions, and outcomes
<methods-participants-interventions-and-outcomes>
- ☐ #strong[\8. Trial design:] Description of trial design including
  type of trial, allocation ratio, and framework.
- ☐ #strong[\9. Study setting:] Description of study settings.
- ☐ #strong[\10. Eligibility criteria:] Inclusion and exclusion criteria
  for participants.
- ☐ #strong[\11. Interventions:] Interventions for each group with
  sufficient detail to allow replication.
- ☐ #strong[\12. Outcomes:] Primary, secondary, and other outcomes.

== Methods: Assignment of interventions (for controlled trials)
<methods-assignment-of-interventions-for-controlled-trials>
- ☐ #strong[\13. Allocation:] Sequence generation, concealment
  mechanism, and implementation.
- ☐ #strong[\14. Blinding (masking):] Who will be blinded and how.

== Methods: Data collection, management, and analysis
<methods-data-collection-management-and-analysis>
- ☐ #strong[\15. Data collection methods:] Plans for assessment and
  collection of outcome, baseline, and other trial data.
- ☐ #strong[\16. Data management:] Plans for data entry, coding,
  security, and storage.
- ☐ #strong[\17. Statistical methods:] Statistical methods for analysing
  primary and secondary outcomes.

== Methods: Monitoring
<methods-monitoring>
- ☐ #strong[\18. Data monitoring:] Plans for data monitoring.
- ☐ #strong[\19. Harms:] Plans for collecting, assessing, reporting, and
  managing solicited and spontaneously reported adverse events and other
  unintended effects of trial interventions or trial conduct.
- ☐ #strong[\20. Auditing:] Frequency and procedures for auditing trial
  conduct.

== Ethics and dissemination
<ethics-and-dissemination>
- ☐ #strong[\21. Research ethics approval:] Plans for seeking research
  ethics committee/institutional review board approval.
- ☐ #strong[\22. Protocol amendments:] Plans for communicating important
  protocol modifications to relevant parties.
- ☐ #strong[\23. Consent or assent:] Who will obtain informed consent or
  assent from potential trial participants or authorized surrogates, and
  how.
- ☐ #strong[\24. Confidentiality:] How personal information about
  potential and enrolled participants will be collected, shared, and
  maintained in order to protect confidentiality before, during, and
  after the trial.
- ☐ #strong[\25. Declaration of interests:] Financial and other
  competing interests for principal investigators for the overall trial
  and each study site.
- ☐ #strong[\26. Access to data:] Statement of who will have access to
  the final trial dataset, and disclosure of contractual agreements that
  limit such access for investigators.
- ☐ #strong[\27. Ancillary and post-trial care:] Provisions, if any, for
  ancillary and post-trial care, and for compensation to those who
  suffer harm from trial participation.
- ☐ #strong[\28. Dissemination policy:] Plans for investigators and
  sponsors to authors and other stakeholders to share trial results.
- ☐ #strong[\29. Authorship eligibility:] Guidelines for authorship
  eligibility for trial publications.
- ☐ #strong[\30. Reproducibility:] Plans for sharing of original data
  and statistical code.

== Appendices
<appendices>
- ☐ #strong[\31. Informed consent materials:] Model consent form and
  other related documentation given to participants and authorized
  surrogates.
- ☐ #strong[\32. Biological specimens:] Plans for collection, laboratory
  evaluation, and storage of biological specimens for genetic or
  molecular analysis in the current trial and for future use in
  ancillary studies, if applicable.

Notes

== Provenance
<provenance>
- Source: See sidecar metadata in `source/archetypes/spirit-2025.yml`
- Version: 2025
- License: CC-BY-4.0
